drugset / Trial / NCT02367352
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
Timeline
- Start
- 2015-03-19
- Primary completion
- 2017-05-23
- Completion
- 2017-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alisertib | Small molecule | 15 mg | Oral |
| Subject | Alisertib | Small molecule | 20 mg | Oral |
| Subject | Alisertib | Small molecule | 25 mg | Oral |
| Background | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |